Share ownership Bright Minds Biosciences Inc.

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 20:48:09 06/02/2026 GMT			5-day change	1st Jan Change
104.31 ^CAD	0.00%		-2.94%	-5.54%

01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-09	Bright Minds Biosciences Closes $175.1 Million Stock Offering	MT

Share class: Bright Minds Biosciences Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,948,489	5,052,710 ( 72.72 %)	0	72.72 %

Major shareholders: Bright Minds Biosciences Inc.

Name	Equities	%	Valuation
Janus Henderson Investors US LLC 14.71 %	1,145,660	14.71 %	89 M $
Janus Henderson Investors US LLC 14.71 %	1,145,660	14.71 %	89 M $
Cormorant Asset Management LP 13.6 %	1,059,331	13.6 %	83 M $
Cormorant Asset Management LP 13.6 %	1,059,331	13.6 %	83 M $
Ian McDonald 12.9 %	1,004,900	12.9 %	78 M $
Vivo Capital LLC 6.442 %	501,617	6.442 %	39 M $
Commodore Capital LP 6.421 %	500,000	6.421 %	39 M $
Commodore Capital LP 6.421 %	500,000	6.421 %	39 M $
Alan Kozikowski 6.17 %	480,500	6.17 %	37 M $
Perceptive Advisors LLC 5.77 %	449,290	5.77 %	35 M $
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	119.89%
Individuals	24.24%
Other	8.4%
State Street Corp.	0.88%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	128.52%
Individuals	24.24%
Australia	0.36%
Switzerland	0.18%
United Kingdom	0.08%
Singapore	0.02%
Canada	0.01%

Based on 1000 largest holdings

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-17 - Q1 2026 Earnings Release (Projected)

More about the company